Imfinzi improved survival in biliary tract cancer
25 October 2021 7:00 BST Imfinzi plus chemotherapy significantly improved overall survival in 1st-line advanced biliary tract cancer in TOPAZ-1 Phase III trial at interim analysis First immunotherapy combination to demonstrate superior clinical outcomesover standard of care in a global, randomised trial in this setting Positive high-level results from the TOPAZ-1 Phase III trial showed Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone